MX2017014311A - Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina. - Google Patents

Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Info

Publication number
MX2017014311A
MX2017014311A MX2017014311A MX2017014311A MX2017014311A MX 2017014311 A MX2017014311 A MX 2017014311A MX 2017014311 A MX2017014311 A MX 2017014311A MX 2017014311 A MX2017014311 A MX 2017014311A MX 2017014311 A MX2017014311 A MX 2017014311A
Authority
MX
Mexico
Prior art keywords
rosuvastatin
losartan
amlodipine
complex formulation
pharmaceutical
Prior art date
Application number
MX2017014311A
Other languages
English (en)
Inventor
Il Kim Yong
Hyun Park Jae
Soo Woo Jong
Taek Im Ho
Jun Cho Hyuk
Yoon Youngsu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2017014311A publication Critical patent/MX2017014311A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composición farmacéutica para prevenir o tratar un trastorno cardiovascular que comprende amlodipino, rosuvastatina y losartán, y una formulación farmacéutica del complejo que comprende una primera parte de la mezcla que contiene amlodipino y rosuvastatina y una según parte de la mezcla que contiene losartán. La composición y formulación de complejo comprende rosuvastatina que tiene un tamaño de partícula (D90) de 50 µm o menos, y exhibe excelente velocidad de disolución, biodisponibilidad, estabilidad y uniformidad de contenido, y por lo tanto pueden ser útiles en industrias farmacéuticas.
MX2017014311A 2015-06-30 2016-06-29 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina. MX2017014311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093714 2015-06-30
PCT/KR2016/006977 WO2017003186A1 (en) 2015-06-30 2016-06-29 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Publications (1)

Publication Number Publication Date
MX2017014311A true MX2017014311A (es) 2018-03-07

Family

ID=57608904

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014311A MX2017014311A (es) 2015-06-30 2016-06-29 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
MX2021005210A MX2021005210A (es) 2015-06-30 2017-11-08 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005210A MX2021005210A (es) 2015-06-30 2017-11-08 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Country Status (6)

Country Link
KR (2) KR20170003459A (es)
CN (2) CN112933093A (es)
MX (2) MX2017014311A (es)
PH (1) PH12017501986A1 (es)
RU (1) RU2724338C2 (es)
WO (1) WO2017003186A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022436A2 (ko) * 2017-07-27 2019-01-31 에리슨제약(주) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法
CN109464407A (zh) * 2018-12-27 2019-03-15 成都恒瑞制药有限公司 瑞舒伐他汀钙快速释放制剂及其制备方法
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CN101528204B (zh) * 2006-10-30 2012-12-12 韩诺生物制约株式会社 包含血管紧张素Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
MA33056B1 (fr) * 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제

Also Published As

Publication number Publication date
KR20180044873A (ko) 2018-05-03
RU2018103213A3 (es) 2019-12-09
WO2017003186A1 (en) 2017-01-05
KR20170003459A (ko) 2017-01-09
RU2724338C2 (ru) 2020-06-23
CN112933093A (zh) 2021-06-11
PH12017501986A1 (en) 2018-03-19
MX2021005210A (es) 2021-06-18
RU2018103213A (ru) 2019-07-31
CN108156807A (zh) 2018-06-12

Similar Documents

Publication Publication Date Title
PH12017501986A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
GB2572721B (en) Active agent-containing articles and product-shipping assemblies for containing the same
EP3697792A4 (en) DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE
IL259119B (en) Biparotropic peptides, a pharmaceutical preparation containing them and drugs for the treatment of cancer containing them
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
MX2018002863A (es) Recubrimiento en polvo y metodo para producir un recubrimiento en polvo.
PH12016500833A1 (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
EP3030614A4 (en) Polymer mixture, multilayer article containing the same, and process of preparing the multilayer article
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
EP3658554A4 (en) DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE
IL262020B (en) Grisiofulvin compound, preparations containing it and its uses
MX2018005349A (es) Articulos de vidrio con revestimientos de oxido de metal y polimero mezclados.
ZA201900421B (en) Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same
EP3320903A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE, VALSARTAN AND ROSUVASTATIN
EP3556352A4 (en) COMPOSITION OF AMPHIPHILIC SEQUENCED COPOLYMER WITH IMPROVED MICELLAR STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING IT
MX368159B (es) Proceso para elaborar tabletas con el uso de radiofrecuencia y partículas disipativas revestidas.
HUP1500618A2 (en) Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
EP3610866A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING A MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTI-CANCER DRUG AS ACTIVE SUBSTANCES
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3330378A4 (en) MODIFIED siRNA, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP3328435A4 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED STORAGE STABILITY AND METHOD FOR THE MANUFACTURE THEREOF
EP3328434A4 (en) PHARMACEUTICAL COMPOSITION HAVING ENHANCED STORAGE STABILITY AND METHOD FOR PREPARING THE SAME
MX2019010000A (es) Composicion nutricional en forma de polvo proporcionada en capsulas para porcion individual.
MX2018001222A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them